WPW
ALXN

Waldron Private Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Waldron Private Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,398
Closed -$234K – 154
2015
Q2 		$234K Sell
1,398
-13
-0.9% -$2.24K 0.09% 103
2015
Q1 		$245K Sell
1,411
-249
-15% -$45.1K 0.1% 97
2014
Q4 		$307K Buy
1,660
+391
+31% +$72.5K 0.13% 66
2014
Q3 		$210K Sell
1,269
-232
-15% -$38.1K 0.1% 106
2014
Q2 		$235K Sell
1,501
-48
-3% -$7.58K 0.11% 102
2014
Q1 		$236K Sell
1,549
-550
-26% -$87.5K 0.11% 99
2013
Q4 		$279K Buy
+2,099
New +$252K 0.13% 78

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Waldron Private Wealth's ALXN Position: Q3 2015 in Review

Waldron Private Wealth sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 1,398 shares — an estimated $234K sold.

Waldron Private Wealth first reported a position in ALXN in Q4 2013 and held it in 7 quarters. The position peaked at $307K in Q4 2014. 515 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

  • Waldron Private Wealth reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Waldron Private Wealth sold 1,398 Alexion Pharmaceuticals shares in Q3 2015, an estimated $234K.
  • Waldron Private Wealth first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 7 quarters.
  • Waldron Private Wealth's Alexion Pharmaceuticals position peaked at $307K in Q4 2014.
  • 515 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Waldron Private Wealth's 13F filing for Q3 2015, filed 13 Nov 2015.